Avalo Therapeutics AVTX Stock
Avalo Therapeutics Price Chart
Avalo Therapeutics AVTX Financial and Trading Overview
| Avalo Therapeutics stock price | 18.03 USD |
| Previous Close | 3.04 USD |
| Open | 3.08 USD |
| Bid | 0 USD x 1000 |
| Ask | 0 USD x 1200 |
| Day's Range | 2.9 - 3.99 USD |
| 52 Week Range | 1.41 - 7.42 USD |
| Volume | 108.76K USD |
| Avg. Volume | 74.98K USD |
| Market Cap | 49.7M USD |
| Beta (5Y Monthly) | 1.616197 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 6.54 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.33 USD |
AVTX Valuation Measures
| Enterprise Value | 45.37M USD |
| Trailing P/E | N/A |
| Forward P/E | -1.6659292 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 2.8640513 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 2.615 |
| Enterprise Value/EBITDA | -1.797 |
Trading Information
Avalo Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.616197 |
| 52-Week Change | -37.37% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 7.42 USD |
| 52 Week Low | 1.41 USD |
| 50-Day Moving Average | 2.95 USD |
| 200-Day Moving Average | 3.96 USD |
AVTX Share Statistics
| Avg. Volume (3 month) | 74.98K USD |
| Avg. Daily Volume (10-Days) | 174.31K USD |
| Shares Outstanding | 13.2M |
| Float | 4.26M |
| Short Ratio | 0.53 |
| % Held by Insiders | 11.62% |
| % Held by Institutions | 56.55% |
| Shares Short | 42.56K |
| Short % of Float | 0.57% |
| Short % of Shares Outstanding | 0.32% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:12 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -170.35% |
| Operating Margin (ttm) | -146.25% |
| Gross Margin | -40.16% |
| EBITDA Margin | -145.49% |
Management Effectiveness
| Return on Assets (ttm) | -32.32% |
| Return on Equity (ttm) | -77794.73% |
Income Statement
| Revenue (ttm) | 17.35M USD |
| Revenue Per Share (ttm) | 1.74 USD |
| Quarterly Revenue Growth (yoy) | -59.50% |
| Gross Profit (ttm) | -7939000 USD |
| EBITDA | -25247000 USD |
| Net Income Avi to Common (ttm) | -29562000 USD |
| Diluted EPS (ttm) | -2.41 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 16.69M USD |
| Total Cash Per Share (mrq) | 1.26 USD |
| Total Debt (mrq) | 21.93M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.828 |
| Book Value Per Share (mrq) | -0.475 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -20736000 USD |
| Levered Free Cash Flow (ttm) | -15296625 USD |
Profile of Avalo Therapeutics
| Country | United States |
| State | MD |
| City | Rockville |
| Address | 540 Gaither Road |
| ZIP | 20850 |
| Phone | 410 522 8707 |
| Website | https://www.avalotx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 20 |
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation. The company's drug candidates include AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as Crohn's disease; Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome; and AVTX-008, a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. It also develops AVTX-803, a L-fucose monosaccharide therapy for treatment of Leukocyte Adhesion Deficiency Type II. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Q&A For Avalo Therapeutics Stock
What is a current AVTX stock price?
Avalo Therapeutics AVTX stock price today per share is 18.03 USD.
How to purchase Avalo Therapeutics stock?
You can buy AVTX shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Avalo Therapeutics?
The stock symbol or ticker of Avalo Therapeutics is AVTX.
Which industry does the Avalo Therapeutics company belong to?
The Avalo Therapeutics industry is Biotechnology.
How many shares does Avalo Therapeutics have in circulation?
The max supply of Avalo Therapeutics shares is 17.8M.
What is Avalo Therapeutics Price to Earnings Ratio (PE Ratio)?
Avalo Therapeutics PE Ratio is 2.75688080 now.
What was Avalo Therapeutics earnings per share over the trailing 12 months (TTM)?
Avalo Therapeutics EPS is 6.54 USD over the trailing 12 months.
Which sector does the Avalo Therapeutics company belong to?
The Avalo Therapeutics sector is Healthcare.
Avalo Therapeutics AVTX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 23724.96 USD — |
+0.61
|
9.88B USD — | 23628.82 USD — | 23946.23 USD — | — - | 9.88B USD — |
| US Tech Health Care IXHC | 1115.96 USD — |
+0.87
|
— — | 1099.74 USD — | 1117.62 USD — | — - | — — |
- {{ link.label }} {{link}}